OTCMKTS:FPMI - Fluoropharma Medical Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.07 0.00 (0.00 %) (As of 02/21/2019 04:00 PM ET)Previous Close$0.0705Today's Range$0.07 - $0.0752-Week Range$0.0296 - $0.15Volume250 shsAverage Volume10,894 shsMarket Capitalization$2.40 millionP/E RatioN/ADividend YieldN/ABeta3.27 ProfileDiscussionChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey. Receive FPMI News and Ratings via Email Sign-up to receive the latest news and ratings for FPMI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:FPMI Previous Symbol CUSIPN/A CIK1402785 Webwww.fluoropharma.com Phone973-744-1565Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares34,262,000Market Cap$2.40 million Next Earnings DateN/A OptionableNot Optionable Fluoropharma Medical (OTCMKTS:FPMI) Frequently Asked Questions What is Fluoropharma Medical's stock symbol? Fluoropharma Medical trades on the OTCMKTS under the ticker symbol "FPMI." How were Fluoropharma Medical's earnings last quarter? Fluoropharma Medical Inc (OTCMKTS:FPMI) posted its quarterly earnings data on Friday, August, 14th. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the Zacks' consensus estimate of ($0.06) by $0.01. View Fluoropharma Medical's Earnings History. Has Fluoropharma Medical been receiving favorable news coverage? Media headlines about FPMI stock have been trending somewhat positive this week, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fluoropharma Medical earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. Who are some of Fluoropharma Medical's key competitors? Some companies that are related to Fluoropharma Medical include IDEXX Laboratories (IDXX), IPSEN S A/S (IPSEY), Neogen (NEOG), Immunomedics (IMMU), Quidel (QDEL), Myriad Genetics (MYGN), Lantheus (LNTH), Meridian Bioscience (VIVO), Quotient (QTNT), Intellia Therapeutics (NTLA), Oxford Immunotec Global (OXFD), Palatin Technologies (PTN), Nymox Pharmaceutical (NYMX), Celldex Therapeutics (CLDX) and Trinity Biotech (TRIB). What other stocks do shareholders of Fluoropharma Medical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fluoropharma Medical investors own include Eyegate Pharmaceuticals (EYEG), Marin Software (MRIN), Medtronic (MDT), First Majestic Silver (AG), Hillenbrand (HI), Freeport-McMoRan (FCX), Axos Financial (AX), Argos Therapeutics (ARGS), Applied Materials (AMAT) and Pareteum (TEUM). Who are Fluoropharma Medical's key executives? Fluoropharma Medical's management team includes the folowing people: Dr. Thomas H. Tulip, CEO, Pres & Director (Age 66)Ms. Tamara Rhein, Chief Financial Officer (Age 47)Mr. Edward L. Lyons Jr., VP of Devel. How do I buy shares of Fluoropharma Medical? Shares of FPMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fluoropharma Medical's stock price today? One share of FPMI stock can currently be purchased for approximately $0.07. How big of a company is Fluoropharma Medical? Fluoropharma Medical has a market capitalization of $2.40 million. What is Fluoropharma Medical's official website? The official website for Fluoropharma Medical is http://www.fluoropharma.com. How can I contact Fluoropharma Medical? Fluoropharma Medical's mailing address is 8 Hillside Avenue Suite 108, Montclair NJ, 07042. The biopharmaceutical company can be reached via phone at 973-744-1565 or via email at [email protected] MarketBeat Community Rating for Fluoropharma Medical (OTCMKTS FPMI)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 45 (Vote Outperform)Underperform Votes: 52 (Vote Underperform)Total Votes: 97MarketBeat's community ratings are surveys of what our community members think about Fluoropharma Medical and other stocks. Vote "Outperform" if you believe FPMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPMI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2019 by MarketBeat.com StaffFeatured Article: What is dollar cost averaging (DCA)?